Lexicon Pharmaceuticals' 'Into the Dark' campaign seeks to raise awareness among HCPs about the risks for recently-discharged heart failure patients

March 6, 2023 02:36 PM ESTUpdated 03:28 PM

Marketing

Lexicon dives ‘into the dark’ days following heart failure hospitalizations with new campaign

Beth Snyder Bulik

Senior Editor

Studies have shown that for heart failure patients, the period after leaving the hospital is a risky time for recurrence. Lexicon Pharmaceuticals wants healthcare providers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lexicon dives ‘into the dark’ days following heart failure hospitalizations with new campaign

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO

Lex­i­con dives ‘in­to the dark’ days fol­low­ing heart fail­ure hos­pi­tal­iza­tions with new cam­paign

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

Lexicon dives ‘into the dark’ days following heart failure hospitalizations with new campaign

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Sofinnova outlines $550M fund after IPOs and M&A deals

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO